Previous studies have indicated that a candidate tumor suppressor gene resides telomeric of the RB1 gene at 13q14. a region that is commonly deleted in B-cell chronic lymphocytic leukemia (B-CLL). In this study, we have evaluated the frequency and minimal region of overlap for 13q deletions in malignant cells from various lymphoid neoplasms. We observed losses at 13q14 in 33/75 (44%) B-CLL cases, four of 16 (25%) non-Hodgkin's lymphoma (NHLI cases, eight of 29 (28%) patients with acute lymphocytic leukemia (ALL), and one of 15 T-cell lines. In some ALL cases, inactivation of the RB1 gene is suggested as the important event in the ENES THAT normally function to prevent or suppress oncogenesis are known as tumor suppressor genes.
also in cases without karyotypic changes! Commonly, the 13q14 deletions did not lead to an inactivation of the RB1 gene.5 A locus, D13S25, located telomeric of the RB1 gene on 13q14, was, however, found by us and others to be completely deleted in some
If the nonrandom finding of structural abnormalities on 13q is of pathogenetic significance, the above data implicates a role for a gene (or genes) telomeric of the RB1 gene in the leukemogenic process of B-CLL. In this study, we have analyzed newly characterized loci around D13S25 aiming at narrowing down the minimal region of overlap in a large sample of primary B-CLL clones. We have also extended our analyses to other lymphoid malignancies.
G MATERIALS AND METHODS

Patients and samples.
The following tumor samples were investigated: (1) acute lymphocytic leukemia (ALL); 29 patients, of whom 4 were T-cell ALL, 1 was B-cell ALL, 1 was undifferentiated ALL, and 23 were pre-B ALL. All cases, except 1, were less than 16 years old at the time of diagnosis. (2) B-CLL; 75 patients. (3) NHLs; 16 patients, of whom one was a high-grade T-cell lymphoma, and the remaining were B-cell lymphomas. Three of these were diffuse centroblastic-centrocytic (CBKC) lymphoma, and 12 were follicular CB/CC. (4) Fifteen T-cell lines; MOLT 13, MOLT 17, MOLT 4, CEM, HUT, P-12, HUT 78, and ALL-SIL.' Separation of cells. Malignant cells were obtained from the peripheral blood, bone marrow, or lymph nodes by separation on Lymphoprep (Nycomed Pharma AS). If required, malignant cells were separated by positive or negative panning, using monoclonal antibodies," or T-cell depletion either by erythrocyte (E)-rosette sedimentation or by separation on nylon wool.'' The malignant cell population used for DNA extraction was in all cases greater than 95% pure, as tested after staining with monoclonal antib0dies.4.~ Nonmalignant cells were obtained by different procedures. In ALL, they were either obtained from peripheral blood or bone marrow after remission induced by chemotherapy or from peripheral blood by exclusion of tumor cells by negative panning followed by a 2-week culture of the remaining cells in medium with phytohemagglutinin (PHA) and interleukin-2 (IL-2), as previously described.' The latter procedure was also used in lymphoma. In B-CLL, normal cells were obtained by (1) granulocyte separation; (2) T-cell-enrichment by E-rosette separation; and (3) culture of T cells?
DNA probes. 13q14 probes: pR3.8 and pR 0.9 are the 3.8-kb and 0.9-kb EcoRI restriction fragments of the 4.7-kb RB cDNA.'* The pH2-42 probe is derived from the chromosome locus D13S25 at 13q14.2.I3 The RBkpt and Mggl5 probes are derived from chromosome 13 cosmid clones, and the latter is selected by specific primers and corresponds to the designated locus D13S319.'4. '5 Several probes served as internal hybridization standards: 10.2 (21q22.3; D21S25),j6 p105-153A (5q11.2-q13.3; D5S39),I7 and pB16 (bcl-2 cDNA clone corresponding to the 1.6-kb 3' part of the first exon).'* DNA analysis and quantitation of band intensity. DNA extraction, digestion with restriction enzyme, agarose gel electrophoresis, Southern blotting, and hybridization were performed as previously described." Scanning densitometry was used to quantitate the various chromosome 13 alleles in the malignant samples. The values were correlated to those obtained using control probes. A reduction in the signal intensity by approximately 50% was determined as hemizygous deletion.
Microsatellite analysis. The sequence of the primers detecting microsatellite polymorphisms at 13q14 are shown in Table 1 .
One of the primers was labeled with y"S-dATP in the presence
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U. S of T4 polynucleotide kinase. A total of 10 pL of polymerase chain reaction (PCR) reaction was amplified for 27 cycles with annealing temperature of 55°C or 58°C. as previously described.2" The radiolabeled PCR products were electrophoresed on 6% of denaturing polyacrylamide gel. The gel was dried and autoradiographed using hyperfilm p-max (Amersham). Absence of or sharply decreased intensity of an allele in the tumor samples was interpreted as loss of heterozy- gosity (LOH). In some cases, loss of 13q material was not detected by Southern blot analysis, although LOH was observed by microsatellite analysis. These cases were interpreted as having lost one allele and duplicated the remaining.
RESULTS
The order of the 13q loci analyzed has been determined as Cen-RBl-RBkpt-D13S319-D13S2S-D13S201-Te1.13"5
The distance between RBI and RBkpt is approximately 50 to 70 kb. Using linkage analysis, the distance between D13S2S and RB 1 has been determined to be 1.3 to 1.7 centim~rgan,'~''~.~' and the physical distance between these markers is less than included. The D13S201 locus was analyzed only by microsatellite markers in ALL and NHLs, and the informative cases are reported. The RBkpt locus was analyzed in four cases of B-CLL. B-CLL. Hemi, or homozygous 13q14 deletions were found in 33 of 75 patients (44%) (Figs 1 and 2 ). The deletion frequency was 16 of 75 (21 %) at the RB 1 gene, 33 of 75 (44%) at the D1 3S3 19 locus, and 29 of 75 (39%) at the D13S25 locus. In 16 cases, large deletions covering all three loci were found. Homozygous deletions of the D13S25 and D13S319 loci were observed in 4 patients, and in another 6 cases the homozygous deletions included only the D 13S3 19 locus. Loss of one allele and duplication of the remaining allele was observed in 2 patients. In 1 case analyzed with the RBkpt probe (CLL74), deletions at the D1 3S3 l9 and the D13S25 loci were observed, whereas no gross deletions were found at the RBkpt and the RBI loci. This observation minimizes the common region of overlap for the deletions to Non-Hodgkin 'S lymphoma. 13q 14 deletions were found in four of 16 patients (25%) (Figs 2 and 3) . Two had large deletions involving at least three loci, and one had a deletion only at the D1 3S3 19 locus. Loss of one allele and duplication of the remaining allele were observed at the D13S3 19 locus in an additional patient. There was no loss at the D13S2.5 locus in this patient as determined by Southern blot and microsatellite. A possible loss at the RBI gene cannot be excluded because the malignant DNA of this patient was not informative for the RB microsatellite marker.
RBkpt-DI3325.
ALL. 13q14 deletions were observed in eight of 29 patients (28%) (Figs 2 and 3) . Six had large deletions involving at least three loci. Two had deletions only involving one locus. D13S3 19 and RBI. respectively. The deletion was homozygous for the RBI gene in one case, which has been previously reported."
T-cell lines. A homozygous deletion at the 3' region of the RBI gene was observed in one cell line (ALL-SIL) (Fig  2) , which had a similar deletion pattern as previous reported cases, ie. deletion extending from intron 17 toward the telomere.'"'" No deletions at the D13S319 and D13S25 loci were found in ALL-SIL. In the remaining 14 cell lines, no gross structural changes were found at the RB 1. D13S3 19 and D13S25 loci.
DISCUSSION
Loss of genetic material on chromosome 13 has been reported in B-CLL."" The D13S25 locus, located telomeric of the RBI gene, is frequently deleted in B-CLL."' In the present study. we investigated the D13S25 region, as well as some newly characterized markers, in an extended material with B-CLL. In all, 13q deletions were observed in 4 4 % of B-CLL cases. The most commonly deleted region was D I3S3 19, and the smallest region of overlap for the deletions was between the RBkpt and the D13S25 loci. These data strongly indicate that a candidate tumor suppressor gene(s) located in the vicinity of D13S319 is involved in the malignant transformation of B-CLL.
The RB tumor suppressor gene has previously been as- signed to 13q 14. Loss of RB 1 gene function is involved in the development of retinoblastoma and has also been suggested to participate in the process leading to malignant transformation in other solid tumors.' RBI gene deletions are rarely seen in ALL, but exceptional cases have been Inactivation of the RBI gene seems to play a role in the malignant transformation of one of the ALL clones and the T-cell line (ALL-SIL), but our data do not exclude the importance of an adjacent gene located between the D13S319 and the RBI in the deletion. In another ALL case, the deletion was present only at the D13S3 l9 locus. Our data thus suggest that the important gene in the 13q deletions of some ALL clones could be the same as the gene deleted in B-CLL. The same conclusion can be made with regard to non-Hodgkin's lymphoma; 4 of I6 cases had deletions at 13q14, and in at least one case, the deletion included only Dl 3S3 19. We conclude that 13q deletions are relatively common in lymphoid neoplasms, and that a novel tumor suppressor gene is located in the vicinity of D13S319. As the relevant gene on 13q14 is defined, which is presently being pursued, the proportion of lymphoid clones with genetic changes in this region may prove to be even higher.
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